A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

Morie Gertz, Martha Lacy, Angela Dispenzieri, B. Cheson, B. Barlogie, R. A. Kyle, G. Palladini, S. Geyer, G. Merlini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

INTRODUCTION: AL is a plasma cell disorder with a median survival of 17 months. Death occurs from deposition of amyloid in tissues and not progressive increase in the plasma cell tumor mass. Prior therapies for amyloidosis have been directed at interrupting the synthesis of the amyloid precursor protein, the immunoglobulin light chain. Previously no agents were available capable of dissolving amyloid deposits. IDOX produces responses by binding to and leading to the catabolism of amyloid deposits. This multicenter study attempted to develop a dosing schedule to confirm those initial results. METHODS: Protocol eligibility required an ejection fraction (EF) greater than 50%, ventricular septal thickness < 20 mm, a serum creatinine less than 2.5 mg/dL, a total bilirubin < 2.1 mg/dL, neutrophils of 1,500/nL and platelets of 100,000/uL. Patients with myeloma, second or third degree AV block, atrial fibrillation or nonsustained ventricular tachycardia were excluded. IDOX was administered IV over 1 hour at a dose of 15 mg/m2 once a week for four consecutive weeks, followed by 8 weeks of observation. The four weekly treatments and 8 weeks of observation were considered one course. Up to four courses were given. RESULTS: Twenty-five previously treated and 15 untreated patients with biopsy-proven AL were entered into this protocol. The median age was 66 years (range 50-80). There were 23 women. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an EF < 60%. One, two, three, four and five organ systems were involved in 22,10,4, 3 and 1 patient respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 5 responses (12.5%) at the twelve-week evaluation. One patient had reduction in the severity of neuropathy proven by EMG and healing of skin lesions. A second patient had urinary protein loss of 52.85 g/d fall to 23.92 g/d and albumin rose 0.5 to 2.1 g/dL. In one patient the alkaline phosphatase fell from 374 to 254 (normal < 250). This patient had no change in his nephrotic-range urinary protein excretion. The fourth patient had resolution of microvascular angina and jaw claudication. The fifth response was in a patient whose liver ultrasound showed a reduction in liver size from 17 to 13.5 cm with reduction in alkaline phosphatase level 1,029 to 783. Eight of the patients have died, of cardiac causes (N=2) not treatment-related or progressive amyloidosis (N=6). Twelve patients experienced grade 3+ non-hematologic toxicities, but only 2 had adverse events attributable to the study treatment. CONCLUSION: Despite the low incidence of toxicity, IDOX administered in this protocol was deemed to be insufficiently active at the current dose to warrant further investigation. Reassessment of the dose based on in vivo pharmacokinetic studies are underway.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART II
StatePublished - 2000

Fingerprint

Amyloid
Liver
Alkaline Phosphatase
Toxicity
Deposits
Immunoglobulin Light Chains
Plasmas
Proteins
Pharmacokinetics
Amyloid beta-Protein Precursor
Amyloidosis
Tumors
Albumins
Skin
Ultrasonics
Tissue
Amyloid Plaques
Microvascular Angina
esorubicin
Primary amyloidosis

ASJC Scopus subject areas

  • Hematology

Cite this

A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). / Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Cheson, B.; Barlogie, B.; Kyle, R. A.; Palladini, G.; Geyer, S.; Merlini, G.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Gertz, M, Lacy, M, Dispenzieri, A, Cheson, B, Barlogie, B, Kyle, RA, Palladini, G, Geyer, S & Merlini, G 2000, 'A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)', Blood, vol. 96, no. 11 PART II.
Gertz, Morie ; Lacy, Martha ; Dispenzieri, Angela ; Cheson, B. ; Barlogie, B. ; Kyle, R. A. ; Palladini, G. ; Geyer, S. ; Merlini, G. / A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{ec54da439b264f678e15413d18c38a22,
title = "A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)",
abstract = "INTRODUCTION: AL is a plasma cell disorder with a median survival of 17 months. Death occurs from deposition of amyloid in tissues and not progressive increase in the plasma cell tumor mass. Prior therapies for amyloidosis have been directed at interrupting the synthesis of the amyloid precursor protein, the immunoglobulin light chain. Previously no agents were available capable of dissolving amyloid deposits. IDOX produces responses by binding to and leading to the catabolism of amyloid deposits. This multicenter study attempted to develop a dosing schedule to confirm those initial results. METHODS: Protocol eligibility required an ejection fraction (EF) greater than 50{\%}, ventricular septal thickness < 20 mm, a serum creatinine less than 2.5 mg/dL, a total bilirubin < 2.1 mg/dL, neutrophils of 1,500/nL and platelets of 100,000/uL. Patients with myeloma, second or third degree AV block, atrial fibrillation or nonsustained ventricular tachycardia were excluded. IDOX was administered IV over 1 hour at a dose of 15 mg/m2 once a week for four consecutive weeks, followed by 8 weeks of observation. The four weekly treatments and 8 weeks of observation were considered one course. Up to four courses were given. RESULTS: Twenty-five previously treated and 15 untreated patients with biopsy-proven AL were entered into this protocol. The median age was 66 years (range 50-80). There were 23 women. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an EF < 60{\%}. One, two, three, four and five organ systems were involved in 22,10,4, 3 and 1 patient respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 5 responses (12.5{\%}) at the twelve-week evaluation. One patient had reduction in the severity of neuropathy proven by EMG and healing of skin lesions. A second patient had urinary protein loss of 52.85 g/d fall to 23.92 g/d and albumin rose 0.5 to 2.1 g/dL. In one patient the alkaline phosphatase fell from 374 to 254 (normal < 250). This patient had no change in his nephrotic-range urinary protein excretion. The fourth patient had resolution of microvascular angina and jaw claudication. The fifth response was in a patient whose liver ultrasound showed a reduction in liver size from 17 to 13.5 cm with reduction in alkaline phosphatase level 1,029 to 783. Eight of the patients have died, of cardiac causes (N=2) not treatment-related or progressive amyloidosis (N=6). Twelve patients experienced grade 3+ non-hematologic toxicities, but only 2 had adverse events attributable to the study treatment. CONCLUSION: Despite the low incidence of toxicity, IDOX administered in this protocol was deemed to be insufficiently active at the current dose to warrant further investigation. Reassessment of the dose based on in vivo pharmacokinetic studies are underway.",
author = "Morie Gertz and Martha Lacy and Angela Dispenzieri and B. Cheson and B. Barlogie and Kyle, {R. A.} and G. Palladini and S. Geyer and G. Merlini",
year = "2000",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - A multicenter phase II trial of 4'-IODO-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Cheson, B.

AU - Barlogie, B.

AU - Kyle, R. A.

AU - Palladini, G.

AU - Geyer, S.

AU - Merlini, G.

PY - 2000

Y1 - 2000

N2 - INTRODUCTION: AL is a plasma cell disorder with a median survival of 17 months. Death occurs from deposition of amyloid in tissues and not progressive increase in the plasma cell tumor mass. Prior therapies for amyloidosis have been directed at interrupting the synthesis of the amyloid precursor protein, the immunoglobulin light chain. Previously no agents were available capable of dissolving amyloid deposits. IDOX produces responses by binding to and leading to the catabolism of amyloid deposits. This multicenter study attempted to develop a dosing schedule to confirm those initial results. METHODS: Protocol eligibility required an ejection fraction (EF) greater than 50%, ventricular septal thickness < 20 mm, a serum creatinine less than 2.5 mg/dL, a total bilirubin < 2.1 mg/dL, neutrophils of 1,500/nL and platelets of 100,000/uL. Patients with myeloma, second or third degree AV block, atrial fibrillation or nonsustained ventricular tachycardia were excluded. IDOX was administered IV over 1 hour at a dose of 15 mg/m2 once a week for four consecutive weeks, followed by 8 weeks of observation. The four weekly treatments and 8 weeks of observation were considered one course. Up to four courses were given. RESULTS: Twenty-five previously treated and 15 untreated patients with biopsy-proven AL were entered into this protocol. The median age was 66 years (range 50-80). There were 23 women. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an EF < 60%. One, two, three, four and five organ systems were involved in 22,10,4, 3 and 1 patient respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 5 responses (12.5%) at the twelve-week evaluation. One patient had reduction in the severity of neuropathy proven by EMG and healing of skin lesions. A second patient had urinary protein loss of 52.85 g/d fall to 23.92 g/d and albumin rose 0.5 to 2.1 g/dL. In one patient the alkaline phosphatase fell from 374 to 254 (normal < 250). This patient had no change in his nephrotic-range urinary protein excretion. The fourth patient had resolution of microvascular angina and jaw claudication. The fifth response was in a patient whose liver ultrasound showed a reduction in liver size from 17 to 13.5 cm with reduction in alkaline phosphatase level 1,029 to 783. Eight of the patients have died, of cardiac causes (N=2) not treatment-related or progressive amyloidosis (N=6). Twelve patients experienced grade 3+ non-hematologic toxicities, but only 2 had adverse events attributable to the study treatment. CONCLUSION: Despite the low incidence of toxicity, IDOX administered in this protocol was deemed to be insufficiently active at the current dose to warrant further investigation. Reassessment of the dose based on in vivo pharmacokinetic studies are underway.

AB - INTRODUCTION: AL is a plasma cell disorder with a median survival of 17 months. Death occurs from deposition of amyloid in tissues and not progressive increase in the plasma cell tumor mass. Prior therapies for amyloidosis have been directed at interrupting the synthesis of the amyloid precursor protein, the immunoglobulin light chain. Previously no agents were available capable of dissolving amyloid deposits. IDOX produces responses by binding to and leading to the catabolism of amyloid deposits. This multicenter study attempted to develop a dosing schedule to confirm those initial results. METHODS: Protocol eligibility required an ejection fraction (EF) greater than 50%, ventricular septal thickness < 20 mm, a serum creatinine less than 2.5 mg/dL, a total bilirubin < 2.1 mg/dL, neutrophils of 1,500/nL and platelets of 100,000/uL. Patients with myeloma, second or third degree AV block, atrial fibrillation or nonsustained ventricular tachycardia were excluded. IDOX was administered IV over 1 hour at a dose of 15 mg/m2 once a week for four consecutive weeks, followed by 8 weeks of observation. The four weekly treatments and 8 weeks of observation were considered one course. Up to four courses were given. RESULTS: Twenty-five previously treated and 15 untreated patients with biopsy-proven AL were entered into this protocol. The median age was 66 years (range 50-80). There were 23 women. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an EF < 60%. One, two, three, four and five organ systems were involved in 22,10,4, 3 and 1 patient respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 5 responses (12.5%) at the twelve-week evaluation. One patient had reduction in the severity of neuropathy proven by EMG and healing of skin lesions. A second patient had urinary protein loss of 52.85 g/d fall to 23.92 g/d and albumin rose 0.5 to 2.1 g/dL. In one patient the alkaline phosphatase fell from 374 to 254 (normal < 250). This patient had no change in his nephrotic-range urinary protein excretion. The fourth patient had resolution of microvascular angina and jaw claudication. The fifth response was in a patient whose liver ultrasound showed a reduction in liver size from 17 to 13.5 cm with reduction in alkaline phosphatase level 1,029 to 783. Eight of the patients have died, of cardiac causes (N=2) not treatment-related or progressive amyloidosis (N=6). Twelve patients experienced grade 3+ non-hematologic toxicities, but only 2 had adverse events attributable to the study treatment. CONCLUSION: Despite the low incidence of toxicity, IDOX administered in this protocol was deemed to be insufficiently active at the current dose to warrant further investigation. Reassessment of the dose based on in vivo pharmacokinetic studies are underway.

UR - http://www.scopus.com/inward/record.url?scp=33748534160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748534160&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748534160

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -